Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...

Only one fifth of individuals with hypertension are estimated to have their BP under control (WHO, 2024). It is thought non-adherence to a clinical management plan is one of the main reasons for poor ...

Q4 2024 Earnings Call Transcript February 28, 2025 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that ...

Data from DELIVER and ACHIEVE Clinicals Trial to be Presented - - Presentation on ACHIEVE ... objectives of management, the potential of the FORCE platform, the potential of DYNE-101 and DYNE-251, and ...

STUDIO CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month is an annual global awareness campaign that ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to le ...

Company still keen to complete deals despite Hookipa merger failing to materialise, says chairman Cathal Friel ...

Novant Health Inc. pitch to investors features two ambitious initiatives: the first: tripling annual revenue from $10 billion ...

Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Good day, and welcome to the RadNet, Inc. Fourth Quarter 2024 Financial Results Conference Call. All participants will be in listen-only ...

Determination of health promotion needs and plan of care including deviations from normal during ... Analysis of reproductive physiology in humans that serves as the foundation for clinical assessment ...